pharmaphorum

Novartis buys NASH biotech IFM Tre in potential $1.575 bn deal

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
The Australian Financial Review

IFM Investors’ $400m Benson Radiology acquisition hits the wall

IFM Investors’ PRP Diagnostic Imaging has withdrawn from its acquisition of South Australia’s Benson Radiology. PRP in early December ousted rival buyout firm Crescent Capital Partners to secure ...
IEEE

Evaluation of Encoder-Only Transformer for Multi-Step Traffic Flow Prediction

Abstract: Traffic flow prediction is critical for Intelligent Transportation Systems to alleviate congestion and optimize traffic management. The existing basic Encoder-Decoder Transformer model for ...
IEEE

An Optimized Model With Encoder-Decoder ConvLSTM for Global Ionospheric Forecasting

Abstract: The ionosphere is vital for satellite navigation and radio communication, but observational limitations necessitate ionospheric forecasting. The least squares collocation (LSC) method is ...